II-35 Elisa Borella PKPD modelling of MEN1611 anti-tumor effect in xenograft models to predict efficacy threshold concentrations in HER2-positive advanced or metastatic breast cancer patient population |
III-27 Elisa Borella Vaborem pharmacokinetics and dose rationale in children |
III-28 Elisa Borella Oritavancin pharmacokinetics and dose rationale in children |